Continuing to expand avenues of public-private collaboration, the TB Alliance recently finalized an arrangement with GlaxoSmithKline to tap the expertise of Dr. Kenneth Duncan. A recognized authority on TB drug discovery, Dr. Duncan has led GSK Action TB program since 1994 and is now devoting a majority of his time to the Alliance. GSK's in-kind support of Dr. Duncan's time will enhance current R&D strategies, specifically the process of scientific proposal evaluation, and assessment of industry partnership opportunities.
"We are pleased that GSK is participating in a hands-on way to help find a faster cure," said Dr. Maria Freire, CEO of the TB Alliance. "By lending a respected authority on TB drug discovery, this mind-share arrangement can further drive our R&D activities."
Dr. Ken Duncan said, "This is a great way for me to contribute my industry and research expertise, and this kind of creative industry partnership is what the Alliance is all about. I can extend my input beyond my membership on the SAC and I'm looking forward to working closely with Mel Spigelman, R&D Director, in the coming months."
Dr. Duncan is also helping to organize the prestigious Gordon Research Conference on TB Drug Discovery, which the Alliance is co-sponsoring.